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Abstract
Objective: Hemoglobin A1c (A1C) has recently been recommended for diagnosing diabetes mellitus and dia-
betes risk (prediabetes). Its performance compared with fasting plasma glucose (FPG) and 2-h post-glucose load
(2HPG) is not well delineated. We compared the performance of A1C with that of FPG and 2HPG in preop-
erative cardiac surgery patients.
Methods: Data from 92 patients without a history of diabetes were analyzed. Patients were classified with
diabetes or prediabetes using established cutoffs for FPG, 2HPG, and A1C. Sensitivity and specificity of the new
A1C criteria were evaluated.
Results: All patients diagnosed with diabetes by A1C also had impaired fasting glucose, impaired glucose
tolerance, or diabetes by other criteria. Using FPG as the reference, sensitivity and specificity of A1C for
diagnosing diabetes were 50% and 96%, and using 2HPG as the reference they were 25% and 95%. Sensitivity
and specificity for identifying prediabetes with FPG as the reference were 51% and 51%, respectively, and with
2HPG were 53% and 51%, respectively. One-third each of patients with prediabetes was identified using FPG,
A1C, or both. When testing A1C and FPG concurrently, the sensitivity of diagnosing dysglycemia increased to
93% stipulating one or both tests are abnormal; specificity increased to 100% if both tests were required to be
abnormal.
Conclusions: In patients before cardiac surgery, A1C criteria identified the largest number of patients with
diabetes and prediabetes. For diagnosing prediabetes, A1C and FPG were discordant and characterized different
groups of patients, therefore altering the distribution of diabetes risk. Simultaneous measurement of FGP and
A1C may be a more sensitive and specific tool for identifying high-risk individuals with diabetes and predia-
betes.
Introduction
Diabetes mellitus is one of the major epidemics of ourera, and approximately 48.3 million people in the United
States will have this diagnosis by year 2050.1,2 Screening for
diabetes should be routinely recommended in current health
care management. Hemoglobin A1c (A1C) criteria have re-
cently been recommended by International Expert Committee
Report3 and adopted by the American Diabetes Association to
diagnose diabetes (A1C ‡ 6.5%) and to identify people at high
risk for diabetes (A1C 5.7–6.4%).4 Unlike current tests such as
fasting plasma glucose (FPG) or 2-h post-glucose load (2HPG)
during an oral glucose tolerance test (OGTT), A1C offers a
practical advantage and obviates the need for an overnight
fast or a glucose load. It additionally tests longer-term gly-
cemic control and has considerable analytic stability.5,6 We
expect that the ease of obtaining an A1C will make it the most
popular preoperative screening test. Also, recent data dem-
onstrating that A1C independently predicts cardiovascular
disease and death will further reinforce its use.7 Despite the
recommendation for the use of A1C, its relationship to FPG
and 2HPG screening remain unclear. Recent studies that
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compared these three diagnostic tests in detecting diabetes
and diabetes risk reported conflicting results.8,9 Most of these
analyses are of large databases or populations.
In this study we investigated the relationship between the
three diabetes screening criteria in a clinical setting. We ex-
amined how the new A1C criteria perform in detecting glu-
cose abnormalities in cardiothoracic surgery patients with no
known history of diabetes mellitus. Patients with heart dis-
ease, especially coronary artery disease, have a high diabetes
risk, and because A1C is a practical test, we suspect it will
become the default preoperative test for glucose abnormali-
ties in this population.
Research Design and Methods
We analyzed baseline data from 92 consecutive patients
with no known diabetes history participating in an ongoing
prospective study of acute blood glucose elevations following
cardiovascular surgery. Study evaluations were obtained in
all subjects during an initial ambulatory assessment preced-
ing cardiothoracic surgery procedures including valve re-
placement, coronary artery bypass grafting, thoracic aortic
corrections, or a combination of these procedures. Subjects
with a history of diabetes or of taking any medication that
interferes with glucose metabolism (glucocorticoids, immu-
nosuppressive agents) were excluded. The study was ap-
proved by the University of Michigan Institutional Review
Board.
After written informed consent was obtained, anthropo-
metric measurements (height, weight, body mass index, and
waist and hip circumference) were recorded, and plasma
glucose andA1Cwere collected after an overnight fast. On the
same study day all subjects underwent an OGTT with a 75-g
oral glucose load (Glucola, NERL Diagnostics LLC, part of
Thermo Scientific, East Providence, RI), and plasma was ob-
tained for glucose measurement 2 h later.
Outcome measures
Glucose tolerance classifications recommended by the
American Diabetes Association were used: FPG < 100mg/dL
was defined as normal, 100–125mg/dL as impaired fasting
glucose (IFG), and ‡ 126mg/dL as diabetes. A 2HPGduring a
75-g OGTT of < 140mg/dL was classified as normal, that
between 140 and 199mg/dL as impaired glucose tolerance
(IGT), and ‡ 200mg/dL as diabetes. A1C of ‡ 6.5% was de-
fined as diabetes, and a level of 5.7–6.4% was defined as
prediabetes.4
Assays
Glucose assays were performed by the glucose oxidase
method on a Cobas Mira chemistry analyzer (Roche Diag-
nostics Corp., Indianapolis, IN). A1C was measured by Na-
tional Glycohemoglobin Standardization Program–certified
immunoassay using whole blood (Pointe Scientific, Inc.,
Canton, MI), standardized to the Diabetes Control and
Complications Trial assay. Hemoglobin variants HbA2, HbC,
and HbS do not interfere with this method.
Statistical analysis
Variables of interest were expressed as mean– SE values,
median (25th, 75th percentile), or percentages as appropriate.
Participants were categorized according to FPG, 2HPG-, and
A1C-based cutpoints for diabetes and prediabetes as de-
scribed above.4 Venn diagrams were constructed to illustrate
the concordance and discordance among FPG, 2HPG-, and
A1C-based classifications. A1C was also analyzed relative to
IFG alone, IGT alone, and combined IFG, IGT, and diabetes.
All analyses were performed using SAS (version 9.1) (SAS
Institute, Cary, NC) or SPSS (version 17) (SPSS, Inc., Chicago,
IL) statistical software.
The sensitivity and specificity of the A1C criteria to detect
diabetes and prediabetes were calculated relative to FPG and
2HPG. Sensitivity is the probability of having an abnormal
A1C in the presence of diabetes or prediabetes. Specificity is
the probability of having a normal A1C in the absence of
diabetes or prediabetes. A similar analysis was performed to
determine the sensitivity and specificity of concurrent testing
of A1C and FPG as a diagnostic tool. The reference used for
determining diabetes or diabetes risk for this analysis was

























n (%) 25 (27) 18 (19.5) 8 (8.6) 24 (26) 1 (1) 3 (3.2) 4 (4.3)
Age (years) 56 – 11.4 62– 12.5 64– 16.7 62 – 13.9 66.0 76– 3.0 72– 7.7
Sex (% male) 52 50 50 63 100 100 50
Race (% white) 96 100 100 92 100 100 100
Family history of diabetes (%) 45.8 39 75 42 100 33 75
BMI (kg/m2) 29.1 – 6.4 29.9 – 6.0 31.1 – 5.0 30.5 – 6.6 31.0 21.9 – 0.3 30.6 – 4.8
Waist circumference (cm) 103 – 19.1 101– 24.7 108 – 15 105– 19.8 121.0 77 – 1.3 105– 20.7
A1C (%) mean 5.23 – 0.3 5.7 – 0.7 5.9 – 0.9 5.9 – 0.2 5.8 5.6 – 0.4 6.9 – 0.3
FPG (mg/dL) mean 87.4 – 7.2 106 – 7.0 114 – 27.5 93.2 – 10.3 135 104 – 4.4 112– 8.9
2HPG (mg/dL) mean 94– 25.13 134.5– 45.2 172 – 13.9 108.4 – 37 89 210 – 6.2 166– 50
Data are mean– SD values or percentages as indicated.
A1C, hemoglobin A1c; BMI, body mass index; FPG, fasting plasma glucose; 2HPG, 2-h post-glucose load.
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FPG or 2HPG, and risk was calculated relative to A1C alone,
FPG alone, and A1C and FPG together. We tested sensitivity
and specificity for either FPG or A1C being positive (screen-
ing) and for both FPG and A1C being positive (diagnosis).
Results
Of 116 patients screened for the study, 12 were excluded
because of rescheduled surgeries, 10 declined to participate,
one withdrew consent, and one did not meet eligibility crite-
ria, so 92 were included. Demographic and clinical charac-
teristics of these participants are shown in Table 1. Subjects
with normal glucose tolerance were younger than those with
prediabetes, and subjects with diabetes were the oldest. There
were no statistically significant differences in the other de-
mographic characteristics.
Twenty-five patients (27%) had normal glucose tolerance
by all three criteria. Diabetes was identified in two (2.2%)
FIG. 1. (a) Venn diagrams for diabetes: individuals meeting criteria for diabetes as (A) hemoglobin A1c (A1C) ‡ 6.5%, 2-h
post-glucose load (2HPG) ‡ 200mg/dL and (B) as A1C ‡ 6.5%, fasting plasma glucose (FPG) ‡ 126mg/dL. (b) Venn diagrams
for prediabetes: individuals meeting criteria for prediabetes as (A) A1C 5.7–6.5%, 2HPG 140–200mg/dL and (B) as A1C 5.7–
6.5%, FPG 100–125mg/dL. (c) Venn diagram indicating abnormality (diabetes or prediabetes) by A1C, FPG, or 2HPG.
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patients by FPG, in four (4.3%) patients by 2HPG, and in five
(5.4%) patients by A1C. Prediabetes was identified in 38
(42.3%) by FPG, in 17 (19.3%) by 2HPG, and in 43 (49.4%) by
A1C. Classification of patients as having diabetes or predia-
betes by the different criteria is shown in Figure 1, as is
overlap between FPG, 2HPG, and A1C. The sensitivity and
specificity of A1C for diagnosing diabetes were 50% and 96%,
respectively, using FPG as the gold standard and 25% and
95%, respectively, using 2HPG (Table 2).
Eighteen (19.5%) patients with abnormal FPG had normal
A1C values. Twenty-four (26%) patients with normal FPG
met the A1C criteria for prediabetes. Eight (8.6%) patients
with abnormal 2HPG had normal A1C values, and 33 (35.8%)
with normal 2HPG had prediabetes by A1C (Fig. 1b). The
sensitivity and specificity of A1C for diagnosing prediabetes
were both 51% using FPG as the gold standard and 53% and
51%, respectively, using 2HPG (Table 2). By combining FPG
with A1C, the sensitivity for detecting diabetes or prediabetes
was 93% when either test was positive, and specificity was
100% when both tests were positive (Table 3).
Discussion
In this study, we analyzed the sensitivity and specificity of
the new A1C criteria4 to detect diabetes and prediabetes
compared with FPG and 2HPG in 92 preoperative cardiac
surgery patients with no history of diabetes. Only five (5.4%)
patients were found to have an A1C value in the diabetes
range. In comparison, FPG and 2-h OGTT identified two and
four patients with diabetes, respectively. One patient eachmet
criteria for diabetes by both A1C and FPG or both A1C and
2HPG (Fig. 1a). Therefore, A1C identified the largest number
of patients with diabetes. All patients with A1C ‡ 6.5% had
another glucose abnormality (IFG, IGT, or diabetes) and
would be identified as dysglycemic by conventional criteria.
These data suggest that abnormalities in glucose tolerance
detected by A1C differ from those detected by FPG or OGTT.
Being an integratedmeasure ofmean glucose excursions, A1C
has the distinct advantage over the other tests of assessing
average glycemic trends over 2–3 months. In contrast, plasma
glucose (both fasting and 2h) assesses only one time point in
glucose metabolism.
Several recent reports have compared A1C and glucose. A
good concordance was found between A1C and FPG for the
diagnosis of diabetes mellitus in a population of more than
6,000 adults.9 In a large cohort of 12,485 participants, Selvin
et al.10 found that A1C strongly predicted the development of
diabetes. The usefulness of A1C as a diagnostic tool varied
according to the criteria used to diagnose diabetes and im-
proved if two FPG values were considered.10 In another re-
cent report, A1C identified a smaller population of patients
with undiagnosed diabetes than FPG and 2HPG, under-
scoring the varying abnormalities assessed by different di-
agnostic tests in different populations.11
In this study of preoperative cardiac surgery patients, the
prevalence of diabetes and prediabetes differed by the diag-
nostic criteria used. A1C identified a larger group of patients
with prediabetes or diabetes than FPG or 2HPG alone. Un-
fortunately, only a portion of the groups overlapped (Fig. 1b),
and different subsets of patients were identified with predi-
abetes by FPG, by 2HPG, and by A1C. Two-thirds of the
cardiac surgery patients had prediabetes by either the A1C or
FPG criterion. Thirty percent of this group would have been
missed using A1C alone and 40% with FPG alone. Studying
an older population, Lipska et al.8 found ‘‘considerable dis-
cordance’’ between FPG and A1C-based diagnosis criteria for
both diabetes and prediabetes. A1C classified a similar-sized
(36%) but discrete group of patients with diabetes or predia-
betes compared with FPG (27.5% with diabetes and 33.6%
with prediabetes), and only a subset (36.3% and 29.7%, re-
spectively) overlapped. The public health implications of
these differences were highlighted by an analysis of the 1999–
2006 National Health and Nutrition Examination Survey da-
tabase.12 A1C classified 8.9 million people with normal FPG
( < 100mg/dL) as having prediabetes, and 37.6 million with
IFG had normal A1C values. A1C identified a large cohort of
patients who would have been considered normal by FPG or
OGTT criteria.
Studies have shown that A1C values are higher in women,
blacks and other ethnic minority populations, and the elder-
ly.8,13–15 Varying dysglycemic mechanisms such as different
rates of hemoglobin glycation and racial presence of hemo-
globinopathies have been suggested causes.16 Other factors
that limit the reliability of A1C include subclinical variation in
red blood cell survival, anemia, and medications.5,17
The strengths of this study are that it is one of the first to
evaluate the use of both FPG and A1C criteria for diagnosing
dysglycemia in a preoperative population and also to assess
performance of A1C relative to both established FPG and









FPG, fasting plasma glucose; 2HPG, 2-h post-glucose load.
Table 3. Sensitivity Analysis: Detecting Diabetes or Prediabetes Using Both Fasting Plasma
Glucose or 2-h Post-Glucose Load as Reference
A1C only FPG
Either A1C or FPG
is abnormal (screening)
Both A1C and FPG
are abnormal (diagnosis)
Sensitivity 63% 85% 93% 53%
Specificity 59% 100% 58% 100%
A1C, hemoglobin A1c; FPG, fasting plasma glucose.
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2HPG criteria, used separately or together. It studied a group
of patients with high diabetes risk using standardized
screening techniques obtained during one preoperative visit
day in all patients.
Limitations of this study include the relatively small sam-
ple size and lack of diversity in the population. Only one set of
FPG and A1C values was available. A small group of this
population had diabetes or prediabetes diagnosed by 2HPG
and would have been missed if only A1C and/or FPG were
tested. Because OGTT is not widely used for screening, this
small population may have less clinical relevance.
It is well known that elevated levels of A1C and FPG confer
risks for future type 2 diabetes and cardiovascular events and
that these risks are curvilinear.18 Patients need to be informed
of these results to make appropriate lifestyle and medical in-
terventions, especially in this high-risk cardiothoracic surgery
population. A1C will identify a different group of patients
than identified by FPG alone. Physicians using either test
alone need to be aware of this discordance. Although other
testing mechanisms have been suggested,19 the practicality of
checking an A1C may increase its routine use in diabetes
screening and overcome its shortcomings. Longer-term trials
are needed to determine if conversion to diabetes or devel-
opment of complications differ among patients identified by
each criterion.
Our data on concurrent FPG and A1C show that sensitivity
and specificity were both impacted depending on the strategy
used for screening and diagnosis. Similar trends for sensitivity
and specificity were reported in an earlier study validating
cutoff points for combined testing before the newA1C criteria
were established.20 An additional study reported a higher
diabetes risk in individuals with elevated A1C and FPG lev-
els, suggesting a role for both FPG and A1C in predicting
diabetes.10 Supporting previous data, the sensitivity and
specificity for diagnosing diabetes in this presurgical cohort
are improved by simultaneous testing of FPG and A1C, and
this could be a practical solution for the interim (Table 3).
Conclusions
In preoperative cardiothoracic surgery patients at high risk
for dysglycemia, A1C performs well for the diagnosis of pre-
diabetes and diabetes. Although A1C identifies a different
group of patients than FPG, its convenience and standardiza-
tion21 may overshadow its limitations. Using a simultaneous
A1C andFPGmeasurement is a better screening tool to identify
diabetes or preoperative diabetes risk in this population.
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